These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 17521671

  • 1. Relationship of immunologic abnormalities and disease stage in multiple sclerosis: implications for therapy.
    Vaknin-Dembinsky A, Weiner HL.
    J Neurol Sci; 2007 Aug 15; 259(1-2):90-4. PubMed ID: 17521671
    [Abstract] [Full Text] [Related]

  • 2. Predicting and preventing the future: actively managing multiple sclerosis.
    Hutchinson M.
    Pract Neurol; 2009 Jun 15; 9(3):133-43, discussion 144. PubMed ID: 19448055
    [Abstract] [Full Text] [Related]

  • 3. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?
    Weiner HL.
    Ann Neurol; 2009 Mar 15; 65(3):239-48. PubMed ID: 19334069
    [Abstract] [Full Text] [Related]

  • 4. The pathogenesis of primary progressive multiple sclerosis: antibody-mediated attack and no repair?
    Pender MP.
    J Clin Neurosci; 2004 Sep 15; 11(7):689-92. PubMed ID: 15337125
    [Abstract] [Full Text] [Related]

  • 5. [Multiple sclerosis: a degenerative disease?].
    Confavreux C, Vukusic S.
    Bull Acad Natl Med; 2008 Mar 15; 192(3):483-91; discussion 492-3. PubMed ID: 18819694
    [Abstract] [Full Text] [Related]

  • 6. The immunology of multiple sclerosis: disease mechanisms and therapeutic targets.
    Holmøy T.
    Minerva Med; 2008 Apr 15; 99(2):119-40. PubMed ID: 18431322
    [Abstract] [Full Text] [Related]

  • 7. Positive and negative implications of tumor necrosis factor neutralization for the pathogenesis of multiple sclerosis.
    Taoufik E, Tseveleki V, Euagelidou M, Emmanouil M, Voulgari-Kokota A, Haralambous S, Probert L.
    Neurodegener Dis; 2008 Apr 15; 5(1):32-7. PubMed ID: 18075273
    [Abstract] [Full Text] [Related]

  • 8. Multiple sclerosis: an infectious syndrome involving Chlamydophila pneumoniae.
    Stratton CW, Wheldon DB.
    Trends Microbiol; 2006 Nov 15; 14(11):474-9. PubMed ID: 16996738
    [Abstract] [Full Text] [Related]

  • 9. Immunologic aspects of multiple sclerosis.
    Boppana S, Huang H, Ito K, Dhib-Jalbut S.
    Mt Sinai J Med; 2011 Nov 15; 78(2):207-20. PubMed ID: 21425265
    [Abstract] [Full Text] [Related]

  • 10. Clinically isolated syndromes: predicting and delaying multiple sclerosis.
    Thrower BW.
    Neurology; 2007 Jun 12; 68(24 Suppl 4):S12-5. PubMed ID: 17562845
    [Abstract] [Full Text] [Related]

  • 11. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.
    Bar-Or A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo D, Gianettoni J, Jalili F, Kachuck N, Lapierre Y, Niino M, Oger J, Price M, Rhodes S, Robinson WH, Shi FD, Utz PJ, Valone F, Weiner L, Steinman L, Garren H.
    Arch Neurol; 2007 Oct 12; 64(10):1407-15. PubMed ID: 17698695
    [Abstract] [Full Text] [Related]

  • 12. Protecting axons in multiple sclerosis.
    Wilkins A, Scolding N.
    Mult Scler; 2008 Sep 12; 14(8):1013-25. PubMed ID: 18632772
    [Abstract] [Full Text] [Related]

  • 13. Depression and immunity: inflammation and depressive symptoms in multiple sclerosis.
    Gold SM, Irwin MR.
    Neurol Clin; 2006 Aug 12; 24(3):507-19. PubMed ID: 16877121
    [Abstract] [Full Text] [Related]

  • 14. [Therapy of multiple sclerosis].
    Simó M.
    Neuropsychopharmacol Hung; 2009 Mar 12; 11(1):23-6. PubMed ID: 19731815
    [Abstract] [Full Text] [Related]

  • 15. The immunopathogenesis of multiple sclerosis.
    Prat E, Martin R.
    J Rehabil Res Dev; 2002 Mar 12; 39(2):187-99. PubMed ID: 12051463
    [Abstract] [Full Text] [Related]

  • 16. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis.
    Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H.
    Neurol Sci; 2006 Mar 12; 27 Suppl 1():S1-7. PubMed ID: 16708174
    [Abstract] [Full Text] [Related]

  • 17. Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary.
    Lopez-Diego RS, Weiner HL.
    Nat Rev Drug Discov; 2008 Nov 12; 7(11):909-25. PubMed ID: 18974749
    [Abstract] [Full Text] [Related]

  • 18. Neuroinflammation in multiple sclerosis: evidence for autoimmune dysregulation, not simple autoimmune reaction.
    Grigoriadis N, Grigoriadis S, Polyzoidou E, Milonas I, Karussis D.
    Clin Neurol Neurosurg; 2006 Mar 12; 108(3):241-4. PubMed ID: 16388896
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic role of beta-interferons in multiple sclerosis.
    Javed A, Reder AT.
    Pharmacol Ther; 2006 Apr 12; 110(1):35-56. PubMed ID: 16229894
    [Abstract] [Full Text] [Related]

  • 20. Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications.
    Stadelmann C.
    Curr Opin Neurol; 2011 Jun 12; 24(3):224-9. PubMed ID: 21455066
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.